Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;93(2):216-222.
doi: 10.1111/cge.13039. Epub 2017 Sep 25.

Metformin as targeted treatment in fragile X syndrome

A B C Dy  1   2   3 , F Tassone  3   4 , M Eldeeb  3   5 , M J Salcedo-Arellano  3   5 , N Tartaglia  6 , R Hagerman  3   5
Affiliations

Metformin as targeted treatment in fragile X syndrome

A B C Dy et al. Clin Genet. 2018 Feb.

Abstract

Background: Individuals with fragile X syndrome (FXS) have both behavioral and medical comorbidities and the latter include obesity in approximately 30% and the Prader-Willi Phenotype (PWP) characterized by severe hyperphagia and morbid obesity in less than 10%. Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults. Recently published studies in the Drosophila model and the knock out mouse model of FXS treated with metformin demonstrate the rescue of multiple phenotypes of FXS.

Materials and methods: We present 7 cases of individuals with FXS who have been treated with metformin clinically. One case with type 2 diabetes, 3 cases with the PWP, 2 adults with obesity and/or behavioral problems and, a young child with FXS. These individuals were clinically treated with metformin and monitored for behavioral changes with the Aberrant Behavior Checklist and metabolic changes with a fasting glucose and HgbA1c.

Results: We found consistent improvements in irritability, social responsiveness, hyperactivity, and social avoidance, in addition to comments from the family regarding improvements in language and conversational skills. No significant side-effects were noted and most patients with obesity lost weight.

Conclusion: We recommend a controlled trial of metformin in those with FXS. Metformin appears to be an effective treatment of obesity including those with the PWP in FXS. Our study suggests that metformin may also be a targeted treatment for improving behavior and language in children and adults with FXS.

Keywords: Prader-Willi-phenotype; fragile X syndrome; metformin; obesity; targeted treatments.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The other authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kidd SA, Lachiewicz A, Barbouth D, et al. Fragile X syndrome: a review of associated medical problems. Pediatrics. 2014;134(5):995–1005. 10.1542/peds.2013-4301. - DOI - PubMed
    1. Muzar Z, Lozano R, Kolevzon A, Hagerman RJ. The neurobiology of the Prader-Willi phenotype of fragile X syndrome. Intractable Rare Dis Res. 2016;5(4):255–261. - PMC - PubMed
    1. Bailey DB, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A. 2008;146(16):2060–2069. 10.1002/ajmg.a.32439. - DOI - PubMed
    1. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord. 2011;3(1):57–67. 10.1007/s11689-010-9067-y. - DOI - PMC - PubMed
    1. Hagerman RJ, Hagerman PJ. Fragile X Syndrome: Diagnosis, Treatment and Research. 3rd ed. Baltimore, Maryland: JHU Press; 2002.

Publication types

MeSH terms